Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Probiotic Claims Hit Regulatory Wall, But Media Gives An Advertising Lift

This article was originally published in The Tan Sheet

Executive Summary

Burgeoning research reaches consumers with information that probiotics help with conditions from irritable bowel syndrome to colds, eczema, constipation and diarrhea. “People absorb that information and then they show up and they buy bugs in a bottle,” says health care marketing consultant Kim Wagner.

You may also be interested in...



Probiotics Market Revolution Needs Supplement Industry As Torchbearer

Supplement firms should take the reins of probiotic research and promotion before the pharmaceutical industry controls the message, suggests Peter Leighton, Abunda Functional Foods CEO.

Probiotics Market Revolution Needs Supplement Industry As Torchbearer

Supplement firms should take the reins of probiotic research and promotion before the pharmaceutical industry controls the message, suggests Peter Leighton, Abunda Functional Foods CEO.

Probiotics Market Revolution Needs Supplement Industry As Torchbearer

Supplement firms should take the reins of probiotic research and promotion before the pharmaceutical industry controls the message, suggests Peter Leighton, Abunda Functional Foods CEO. Interest in manipulating the microbiome for therapeutic effect has garnered interest from pharma giants including J&J.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel